Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel Free OFIX Stock Alerts

Orthofix Medical (OFIX) Financials

Orthofix Medical logo
$9.09 -0.12 (-1.30%)
Closing price 04:00 PM Eastern
Extended Trading
$9.10 +0.02 (+0.17%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Orthofix Medical

Annual Income Statements for Orthofix Medical

This table shows Orthofix Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.81 3.06 6.22 14 -28 2.52 -38 -20 -151 -126 -92
Consolidated Net Income / (Loss)		 -2.81 3.06 6.22 14 -28 2.52 -38 -20 -151 -126 -92
Net Income / (Loss) Continuing Operations		 -2.34 3.50 7.29 14 -28 2.52 -38 -20 -151 -126 -92
Total Pre-Tax Income 		8.51 19 36 23 -27 -0.37 -13 -18 -149 -124 -91
Total Operating Income		 9.26 21 41 30 -19 -6.27 -8.32 -13 -139 -85 -81
Total Gross Profit		 310 322 341 356 359 305 350 337 486 546 566
Total Revenue		 396 410 434 453 460 407 464 461 747 799 822
Operating Revenue		 396 410 434 453 460 407 464 461 747 799 822
Total Cost of Revenue		 87 88 93 97 101 102 115 124 260 254 256
Operating Cost of Revenue		 87 88 93 97 101 102 115 124 260 254 256
Total Operating Expenses		 301 301 300 326 378 311 358 350 625 631 647
Selling, General & Admin Expense		 87 76 72 83 86 68 69 309 530 533 554
Research & Development Expense		 26 29 30 33 35 39 50 49 80 74 66
Amortization Expense		 - - - 4.32 34 -0.50 18 -7.40 15 24 27
Total Other Income / (Expense), net		 -0.75 -2.04 -4.42 -7.21 -8.27 5.90 -5.18 -4.44 -9.57 -39 -9.38
Interest Expense		 0.49 -0.76 0.42 0.83 0.12 2.48 1.84 1.29 8.63 30 17
Other Income / (Expense), net		 -0.26 -2.81 -4.00 -6.38 -8.14 8.38 -3.34 -3.15 -0.94 -9.63 8.11
Income Tax Expense		 11 16 29 9.07 1.41 -2.89 25 2.04 2.72 2.12 1.38
Basic Earnings per Share		 ($0.15) $0.17 $0.34 $0.73 ($1.51) $0.13 ($1.95) ($0.98) ($4.12) ($3.30) ($2.33)
Weighted Average Basic Shares Outstanding		 18.80M 18.14M 18.12M 18.49M 18.90M 19.27M 19.69M 20.05M 36.73M 38.13M 39.60M
Diluted Earnings per Share		 ($0.15) $0.17 $0.34 $0.72 ($1.51) $0.13 ($1.95) ($0.98) ($4.12) ($3.30) ($2.33)
Weighted Average Diluted Shares Outstanding		 18.80M 18.46M 18.50M 18.91M 18.90M 19.39M 19.69M 20.05M 36.73M 38.13M 39.60M
Weighted Average Basic & Diluted Shares Outstanding		 18.70M 18M 18.30M 18.90M 19.18M 19.51M 19.85M 36.46M 37.41M 39.02M 40.14M

Quarterly Income Statements for Orthofix Medical

This table shows Orthofix Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -22 -36 -33 -27 -29 -53 -14 -23 -2.22 -21 -16
Consolidated Net Income / (Loss)		 -22 -36 -33 -27 -29 -53 -14 -23 -2.22 -21 -16
Net Income / (Loss) Continuing Operations		 -22 -36 -33 -27 -29 -53 -14 -23 -2.22 -21 -16
Total Pre-Tax Income 		-22 -35 -32 -27 -30 -52 -14 -22 -2.19 -21 -15
Total Operating Income		 -18 -29 -25 -19 -11 -49 -16 -17 0.49 -14 -8.13
Total Gross Profit		 137 127 135 135 149 122 140 149 156 140 150
Total Revenue		 199 189 199 197 216 194 203 206 220 197 211
Operating Revenue		 199 189 199 197 216 194 203 206 220 197 211
Total Cost of Revenue		 64 61 64 62 67 72 64 57 64 57 61
Operating Cost of Revenue		 64 61 64 62 67 72 64 57 64 57 61
Total Operating Expenses		 155 157 160 154 160 170 156 166 156 154 158
Selling, General & Admin Expense		 420 132 134 130 433 133 136 148 137 135 138
Research & Development Expense		 19 19 18 17 19 20 16 15 15 15 16
Amortization Expense		 3.72 5.40 7.39 6.52 5.03 18 3.11 2.69 3.72 3.75 3.87
Total Other Income / (Expense), net		 -3.73 -5.83 -7.45 -7.74 -18 -3.26 1.78 -5.22 -2.69 -6.40 -6.86
Interest Expense		 4.50 4.56 4.94 5.21 15 4.51 3.95 4.68 4.35 5.66 6.09
Other Income / (Expense), net		 0.77 -1.27 -2.51 -2.53 -3.31 1.25 5.73 -0.54 1.67 -0.73 -0.78
Income Tax Expense		 0.13 0.85 1.08 0.75 -0.56 0.96 -0.14 0.53 0.03 0.07 0.80
Basic Earnings per Share		 ($0.57) ($0.95) ($0.88) ($0.71) ($0.76) ($1.35) ($0.36) ($0.57) ($0.05) ($0.52) ($0.39)
Weighted Average Basic Shares Outstanding		 36.73M 37.74M 38.02M 38.49M 38.13M 39.19M 39.50M 39.77M 39.60M 40.45M 40.91M
Diluted Earnings per Share		 ($0.57) ($0.95) ($0.88) ($0.71) ($0.76) ($1.35) ($0.36) ($0.57) ($0.05) ($0.52) ($0.39)
Weighted Average Diluted Shares Outstanding		 36.73M 37.74M 38.02M 38.49M 38.13M 39.19M 39.50M 39.77M 39.60M 40.45M 40.91M
Weighted Average Basic & Diluted Shares Outstanding		 37.41M 37.53M 38.17M 38.21M 39.02M 39.18M 39.49M 39.60M 40.14M 40.42M 40.73M

Annual Cash Flow Statements for Orthofix Medical

This table details how cash moves in and out of Orthofix Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 27 -9.72 27 -8.97 -1.79 26 -8.97 -37 -13 48 -0.62
Net Cash From Operating Activities		 44 59 39 50 32 74 18 -12 -46 26 33
Net Cash From Continuing Operating Activities		 44 59 39 50 32 74 18 -12 -46 26 33
Net Income / (Loss) Continuing Operations		 -2.81 3.06 6.22 14 -28 2.52 -38 -20 -151 -126 -92
Consolidated Net Income / (Loss)		 -2.81 3.06 6.22 14 -28 2.52 -38 -20 -151 -126 -92
Depreciation Expense		 21 21 20 19 25 31 30 29 53 60 77
Amortization Expense		 1.75 1.57 1.71 1.02 3.78 3.73 3.50 3.06 44 28 5.93
Non-Cash Adjustments To Reconcile Net Income		 10 21 21 23 30 14 32 37 65 74 65
Changes in Operating Assets and Liabilities, net		 13 13 -10 -6.59 2.49 23 -8.02 -61 -56 -10 -22
Net Cash From Investing Activities		 -38 -22 -16 -61 -23 -52 -23 -25 -33 -28 -35
Net Cash From Continuing Investing Activities		 -38 -22 -16 -61 -23 -52 -23 -25 -33 -28 -35
Purchase of Property, Plant & Equipment		 -27 -16 -15 -14 -19 -15 -18 -23 -62 -35 -35
Divestitures		 - - 0.47 - - - 0.00 0.00 29 0.00 0.00
Sale and/or Maturity of Investments		 - - - - - - - 0.13 0.00 7.40 0.00
Other Investing Activities, net		 - -3.61 - - - - -1.25 0.00 -0.50 -0.10 0.03
Net Cash From Financing Activities		 25 -46 3.54 2.99 -11 3.25 -3.62 -0.08 65 51 -0.79
Net Cash From Continuing Financing Activities		 25 -46 3.54 2.99 -11 3.25 -3.62 -0.08 65 51 -0.79
Repayment of Debt		 -1.83 - -0.45 -0.68 -3.02 -102 -0.95 -0.09 -81 -146 -0.53
Payment of Dividends		 - - - - - - 0.00 0.00 -27 0.00 0.00
Issuance of Debt		 34 - - 0.00 0.00 100 0.00 0.00 175 198 0.00
Issuance of Common Equity		 5.25 20 7.78 7.10 12 7.60 8.82 4.34 5.13 6.26 5.93
Other Financing Activities, net		 -1.55 -2.41 -3.80 -3.43 -19 -2.82 -11 -4.32 -6.05 -7.02 -6.18
Effect of Exchange Rate Changes		 -3.14 -0.74 1.18 -0.88 -0.21 1.24 -0.82 -1.00 0.62 -0.94 1.41

Quarterly Cash Flow Statements for Orthofix Medical

This table details how cash moves in and out of Orthofix Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 4.09 -8.29 -0.60 3.69 53 -25 8.24 -2.74 19 36 -16
Net Cash From Operating Activities		 -6.69 -19 8.98 12 24 -18 12 12 28 -18 -6.22
Net Cash From Continuing Operating Activities		 -6.69 -19 8.98 12 24 -18 12 12 28 -18 -6.22
Net Income / (Loss) Continuing Operations		 -22 -36 -33 -27 -29 -53 -14 -23 -2.22 -21 -16
Consolidated Net Income / (Loss)		 -22 -36 -33 -27 -29 -53 -14 -23 -2.22 -21 -16
Depreciation Expense		 14 15 14 15 16 34 17 13 13 13 13
Amortization Expense		 10 4.53 4.56 4.66 14 1.25 1.13 1.58 1.98 1.06 1.09
Non-Cash Adjustments To Reconcile Net Income		 7.07 18 25 17 14 22 19 13 11 10 17
Changes in Operating Assets and Liabilities, net		 -16 -20 -1.32 2.21 8.39 -22 -12 7.90 3.83 -22 -22
Net Cash From Investing Activities		 -15 -11 -9.72 -5.86 -1.14 -6.74 -7.10 -9.89 -11 -11 -13
Net Cash From Continuing Investing Activities		 -15 -11 -9.72 -5.86 -1.14 -6.74 -7.10 -9.89 -11 -11 -13
Purchase of Property, Plant & Equipment		 -16 -11 -9.34 -5.32 -9.67 -6.74 -7.11 -9.90 -11 -11 -13
Net Cash From Financing Activities		 25 21 0.23 -2.46 31 -0.65 2.64 -5.15 2.38 64 2.45
Net Cash From Continuing Financing Activities		 25 21 0.23 -2.46 31 -0.65 2.64 -5.15 2.38 64 2.45
Issuance of Common Equity		 2.75 0.00 3.19 0.12 2.95 0.05 3.01 0.04 2.84 0.00 2.63
Other Financing Activities, net		 -0.31 -2.00 -2.12 -2.35 -0.55 -0.19 -0.35 -5.19 -0.46 -0.03 -0.18
Effect of Exchange Rate Changes		 0.56 -0.28 -0.09 0.34 -0.90 0.49 1.05 -0.10 -0.03 -0.09 -0.05

Annual Balance Sheets for Orthofix Medical

This table presents Orthofix Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 400 372 405 467 496 526 477 459 925 893 851
Total Current Assets		 212 194 252 245 261 270 270 256 420 433 417
Cash & Equivalents		 64 40 81 70 70 96 88 51 33 83 82
Restricted Cash		 - 14 - 2.57 0.68 0.53 - 0.00 4.65 2.50 3.09
Accounts Receivable		 60 58 63 78 87 72 79 83 128 135 136
Inventories, net		 58 63 81 77 82 85 83 100 222 189 172
Prepaid Expenses		 31 19 26 18 21 17 20 22 32 23 24
Plant, Property, & Equipment, net		 52 49 45 43 63 64 59 58 159 140 129
Total Noncurrent Assets		 136 129 108 179 172 192 148 144 346 320 304
Goodwill		 54 54 54 72 71 84 71 71 195 195 195
Intangible Assets		 5.30 7.46 10 52 54 61 53 47 117 99 73
Noncurrent Deferred & Refundable Income Taxes		 57 47 23 33 35 25 - - - - 0.00
Other Noncurrent Operating Assets		 19 20 21 22 12 22 24 26 33 26 37
Total Liabilities & Shareholders' Equity		 400 372 405 467 496 526 477 459 925 893 851
Total Liabilities		 110 109 109 131 168 169 140 122 327 390 401
Total Current Liabilities		 82 83 79 86 85 104 106 84 165 169 170
Accounts Payable		 16 14 18 18 20 23 26 28 58 49 58
Other Current Liabilities		 66 69 61 68 65 81 79 56 106 120 112
Total Noncurrent Liabilities		 28 25 29 45 83 65 34 38 161 222 230
Long-Term Debt		 - - - - - - - 0.00 93 157 157
Other Noncurrent Operating Liabilities		 28 25 29 45 83 65 34 38 68 65 73
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 290 263 297 335 328 357 337 337 599 503 450
Total Preferred & Common Equity		 290 263 297 335 328 357 337 337 599 503 450
Total Common Equity		 290 263 297 335 328 357 337 337 599 503 450
Common Stock		 234 206 222 245 273 294 316 337 750 784 818
Retained Earnings		 63 64 70 87 58 59 21 1.25 -150 -276 -368
Accumulated Other Comprehensive Income / (Loss)		 -6.23 -6.58 3.79 3.30 -3.04 3.25 0.00 -1.38 -1.29 -4.30 0.62

Quarterly Balance Sheets for Orthofix Medical

This table presents Orthofix Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 917 901 906 906 882 868 823 837 833 887 873
Total Current Assets		 410 399 394 399 386 386 390 396 394 462 446
Cash & Equivalents		 50 38 34 27 26 30 58 66 63 120 104
Restricted Cash		 - - - 2.50 2.50 2.50 2.50 3.08 3.09 0.59 0.60
Accounts Receivable		 113 112 114 126 125 125 132 130 131 138 136
Inventories, net		 222 222 222 219 210 206 174 173 174 178 184
Prepaid Expenses		 25 27 24 25 22 23 24 25 23 25 21
Plant, Property, & Equipment, net		 137 141 153 158 154 147 131 129 130 125 131
Total Noncurrent Assets		 370 361 359 349 342 335 302 312 308 300 296
Goodwill		 203 192 195 195 195 195 195 195 195 195 195
Intangible Assets		 122 126 121 113 108 105 81 79 76 69 66
Noncurrent Deferred & Refundable Income Taxes		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 45 44 43 41 39 35 26 38 38 35 35
Total Liabilities & Shareholders' Equity		 917 901 906 906 882 868 823 837 833 887 873
Total Liabilities		 253 261 290 336 336 342 365 379 390 451 444
Total Current Liabilities		 138 142 153 151 156 162 144 148 160 161 157
Accounts Payable		 46 51 53 57 50 47 45 45 50 55 64
Other Current Liabilities		 92 90 99 90 101 109 99 103 109 106 93
Total Noncurrent Liabilities		 115 119 138 185 180 180 221 230 230 290 287
Long-Term Debt		 45 51 70 115 113 112 157 157 157 221 222
Other Noncurrent Operating Liabilities		 70 68 68 70 67 68 64 73 73 69 65
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 664 640 615 570 546 526 458 458 442 435 429
Total Preferred & Common Equity		 664 640 615 570 546 526 458 458 442 435 429
Total Common Equity		 664 640 615 570 546 526 458 458 442 435 429
Common Stock		 725 739 745 757 768 774 790 801 808 824 834
Retained Earnings		 -60 -99 -128 -186 -220 -247 -329 -343 -366 -389 -405
Accumulated Other Comprehensive Income / (Loss)		 -0.95 -0.11 -1.86 -0.66 -2.73 -0.90 -2.56 0.91 0.63 0.14 -0.28

Annual Metrics And Ratios for Orthofix Medical

This table displays calculated financial ratios and metrics derived from Orthofix Medical's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 18,889,815.00 17,826,136.00 18,231,334.00 18,920,827.00 19,055,154.00 19,333,698.00 19,745,269.00 - - - 39,599,659.00
DEI Adjusted Shares Outstanding		 18,889,815.00 17,826,136.00 18,231,334.00 18,920,827.00 19,055,154.00 19,333,698.00 19,745,269.00 - - - 39,599,659.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.15 0.17 0.34 0.73 -1.49 0.13 -1.94 - - - -2.33
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -1.44% 3.35% 5.87% 4.43% 1.53% -11.61% 14.25% -0.81% 61.77% 7.27% 2.85%
EBITDA Growth		 -22.26% 28.42% 44.19% -26.00% -96.43% 2,247.81% -41.09% -26.96% -377.47% 85.97% 263.00%
EBIT Growth		 -36.83% 102.99% 101.56% -35.57% -213.55% 107.85% -651.21% -40.83% -753.02% 32.71% 22.20%
NOPAT Growth		 50.53% 251.99% 111.14% 122.12% -172.40% 66.64% -32.70% -59.57% -948.46% 39.17% 3.77%
Net Income Growth		 67.10% 208.79% 103.63% 121.93% -306.08% 108.84% -1,624.79% 48.54% -666.60% 16.78% 26.83%
EPS Growth		 67.39% 213.33% 100.00% 111.76% -309.72% 108.61% -1,600.00% 49.74% -320.41% 19.90% 29.39%
Operating Cash Flow Growth		 -14.76% 35.46% -34.03% 28.09% -35.83% 131.86% -75.13% -162.45% -296.54% 156.37% 29.30%
Free Cash Flow Firm Growth		 -102.73% 2,697.33% -89.22% -1,408.63% 75.78% -0.45% 171.31% -1,002.75% -906.34% 104.65% -122.64%
Invested Capital Growth		 -0.76% -7.55% 2.82% 22.17% -2.27% 1.09% -4.21% 14.88% 129.01% -12.35% -9.07%
Revenue Q/Q Growth		 1.11% 0.96% 1.96% 0.93% 0.09% -0.94% 1.63% -0.61% 11.50% 2.12% 0.52%
EBITDA Q/Q Growth		 697.36% 82.30% 30.05% -11.20% -75.20% 8.51% -42.79% 16.95% 10.42% 59.89% 20.08%
EBIT Q/Q Growth		 126.49% -18.15% 60.51% -18.36% -35.59% 147.37% -432.33% 12.80% -8.35% 2.84% 18.78%
NOPAT Q/Q Growth		 85.25% -61.41% 860.82% 120.84% -79.29% -6.64% 86.21% -14.61% -5.52% 7.48% 12.82%
Net Income Q/Q Growth		 76.54% -68.37% 338.55% 112.22% 9.00% -89.33% -156.80% 56.59% -11.09% -5.86% 22.60%
EPS Q/Q Growth		 76.19% -66.67% 277.78% 111.76% 8.48% -89.26% -261.11% 60.96% -5.64% -6.11% 23.36%
Operating Cash Flow Q/Q Growth		 4.49% 6.51% 30.76% -14.93% -22.21% 16.19% -36.26% -447.60% -24.63% 656.54% 13.50%
Free Cash Flow Firm Q/Q Growth		 92.09% 22.06% 154.12% -7.63% -166.11% 75.82% 110.43% -454.23% -0.93% 190.27% -138.68%
Invested Capital Q/Q Growth		 -2.94% -7.43% -6.89% -1.46% 3.33% -5.30% -11.55% 1.52% 0.54% -6.12% -2.14%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 78.18% 78.56% 78.55% 78.67% 78.13% 74.94% 75.26% 73.18% 65.24% 68.28% 68.83%
EBITDA Margin		 7.99% 9.92% 13.52% 9.58% 0.34% 8.95% 4.62% 3.40% -5.83% -0.76% 1.21%
Operating Margin		 2.33% 5.14% 9.41% 6.64% -4.08% -1.54% -1.79% -2.88% -18.66% -10.58% -9.90%
EBIT Margin		 2.27% 4.46% 8.48% 5.23% -5.85% 0.52% -2.51% -3.56% -18.79% -11.79% -8.92%
Profit (Net Income) Margin		 -0.71% 0.75% 1.43% 3.05% -6.19% 0.62% -8.26% -4.29% -20.31% -15.76% -11.21%
Tax Burden Percent		 -33.02% 16.06% 17.10% 60.35% 105.22% -683.97% 284.39% 111.54% 101.88% 101.71% 101.52%
Interest Burden Percent		 94.56% 104.18% 98.87% 96.51% 100.45% -17.40% 115.76% 107.85% 106.10% 131.44% 123.85%
Effective Tax Rate		 127.53% 81.62% 79.96% 39.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1.12% 1.78% 3.85% 7.59% -5.05% -1.70% -2.29% -3.47% -20.69% -9.63% -10.39%
ROIC Less NNEP Spread (ROIC-NNEP)		 -0.73% 3.16% 6.74% 13.26% 16.43% -9.95% 32.98% 11.63% -1,851.80% -114.05% -59.43%
Return on Net Nonoperating Assets (RNNOA)		 0.17% -0.67% -1.63% -3.22% -3.53% 2.43% -8.78% -2.39% -11.68% -13.24% -8.95%
Return on Equity (ROE)		 -0.95% 1.10% 2.22% 4.37% -8.59% 0.74% -11.06% -5.86% -32.36% -22.87% -19.34%
Cash Return on Invested Capital (CROIC)		 -0.36% 9.62% 1.06% -12.37% -2.75% -2.78% 2.02% -17.32% -99.11% 3.53% -0.90%
Operating Return on Assets (OROA)		 2.27% 4.73% 9.47% 5.44% -5.60% 0.41% -2.33% -3.51% -20.24% -10.36% -8.41%
Return on Assets (ROA)		 -0.71% 0.79% 1.60% 3.17% -5.92% 0.49% -7.66% -4.22% -21.88% -13.86% -10.57%
Return on Common Equity (ROCE)		 -0.95% 1.10% 2.22% 4.37% -8.59% 0.74% -11.06% -5.86% -32.36% -22.87% -19.34%
Return on Equity Simple (ROE_SIMPLE)		 -0.97% 1.16% 2.10% 4.12% -8.69% 0.71% -11.39% -5.86% -25.29% -25.04% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.55 3.87 8.18 18 -13 -4.39 -5.82 -9.29 -97 -59 -57
NOPAT Margin		 -0.64% 0.95% 1.88% 4.01% -2.86% -1.08% -1.25% -2.02% -13.07% -7.41% -6.93%
Net Nonoperating Expense Percent (NNEP)		 -0.39% -1.39% -2.89% -5.67% -21.48% 8.26% -35.26% -15.10% 1,831.12% 104.42% 49.03%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -2.76% -14.05% -8.97% -9.38%
Cost of Revenue to Revenue		 21.82% 21.44% 21.45% 21.33% 21.87% 25.06% 24.74% 26.82% 34.93% 31.72% 31.17%
SG&A Expenses to Revenue		 21.98% 18.65% 16.57% 18.38% 18.61% 16.71% 14.93% 67.02% 71.16% 66.61% 67.41%
R&D to Revenue		 6.66% 7.03% 6.85% 7.33% 7.53% 9.61% 10.68% 10.65% 10.76% 9.21% 8.01%
Operating Expenses to Revenue		 75.84% 73.42% 69.15% 72.03% 82.21% 76.48% 77.05% 76.06% 83.91% 78.86% 78.73%
Earnings before Interest and Taxes (EBIT)		 9.00 18 37 24 -27 2.12 -12 -16 -140 -94 -73
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 32 41 59 43 1.55 36 21 16 -43 -6.09 9.93
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.55 2.45 3.36 2.96 2.69 2.33 1.82 1.22 0.83 1.33 1.33
Price to Tangible Book Value (P/TBV)		 3.20 3.19 4.29 4.70 4.35 3.91 2.88 1.88 1.73 3.19 3.29
Price to Revenue (P/Rev)		 1.87 1.57 2.30 2.19 1.91 2.04 1.32 0.89 0.66 0.83 0.73
Price to Earnings (P/E)		 0.00 211.04 160.25 71.91 0.00 330.14 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.47% 0.62% 1.39% 0.00% 0.30% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.99 2.82 4.25 3.50 3.15 2.82 2.11 1.26 0.84 1.29 1.29
Enterprise Value to Revenue (EV/Rev)		 1.71 1.44 2.11 2.03 1.76 1.81 1.13 0.78 0.74 0.92 0.82
Enterprise Value to EBITDA (EV/EBITDA)		 21.38 14.53 15.62 21.22 522.30 20.17 24.54 23.00 0.00 0.00 67.71
Enterprise Value to EBIT (EV/EBIT)		 75.26 32.36 24.89 38.84 0.00 347.11 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 152.62 112.04 50.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 15.52 10.00 23.51 18.45 25.27 9.88 28.47 0.00 0.00 28.64 20.17
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 28.16 405.07 0.00 0.00 0.00 102.43 0.00 0.00 34.04 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.31 0.35
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.31 0.35
Financial Leverage		 -0.23 -0.21 -0.24 -0.24 -0.22 -0.24 -0.27 -0.21 0.01 0.12 0.15
Leverage Ratio		 1.34 1.39 1.39 1.38 1.45 1.49 1.44 1.39 1.48 1.65 1.83
Compound Leverage Factor		 1.27 1.45 1.37 1.33 1.46 -0.26 1.67 1.50 1.57 2.17 2.27
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.61% 23.79% 25.91%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.18% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.43% 23.79% 25.91%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 86.39% 76.21% 74.09%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.17 -25.77 15.85
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.30 -11.70 7.28
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.14 -25.77 15.85
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.97 -2.65 -2.76
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.58 -1.20 -1.27
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.96 -2.65 -2.76
Altman Z-Score		 5.72 5.42 7.63 6.35 4.48 4.27 4.00 3.37 1.32 1.50 1.32
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.59 2.33 3.17 2.85 3.07 2.60 2.55 3.06 2.54 2.57 2.45
Quick Ratio		 1.51 1.17 1.82 1.72 1.84 1.62 1.57 1.60 0.98 1.29 1.28
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.81 21 2.26 -30 -7.17 -7.20 5.14 -46 -467 22 -4.91
Operating Cash Flow to CapEx		 194.71% 359.52% 265.75% 367.26% 168.62% 479.64% 103.88% -49.82% -73.74% 73.95% 96.31%
Free Cash Flow to Firm to Interest Expense		 -1.65 0.00 5.44 -35.74 -58.76 -2.90 2.80 -35.99 -54.05 0.73 -0.28
Operating Cash Flow to Interest Expense		 89.18 0.00 93.68 60.29 262.57 29.91 10.06 -8.96 -5.30 0.87 1.91
Operating Cash Flow Less CapEx to Interest Expense		 43.38 0.00 58.43 43.87 106.85 23.68 0.38 -26.94 -12.49 -0.31 -0.07
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.00 1.06 1.12 1.04 0.96 0.80 0.93 0.99 1.08 0.88 0.94
Accounts Receivable Turnover		 6.54 6.96 7.15 6.42 5.59 5.11 6.15 5.71 7.07 6.08 6.08
Inventory Turnover		 1.47 1.45 1.29 1.22 1.26 1.22 1.37 1.35 1.62 1.23 1.42
Fixed Asset Turnover		 7.86 8.10 9.22 10.30 8.71 6.44 7.56 7.84 6.86 5.35 6.11
Accounts Payable Turnover		 5.84 5.72 5.73 5.35 5.31 4.74 4.64 4.57 6.06 4.73 4.78
Days Sales Outstanding (DSO)		 55.79 52.41 51.02 56.87 65.29 71.48 59.32 63.94 51.66 59.99 60.02
Days Inventory Outstanding (DIO)		 247.64 251.17 283.79 298.75 288.87 299.18 266.19 270.51 225.92 296.21 257.61
Days Payable Outstanding (DPO)		 62.46 63.87 63.68 68.18 68.70 77.03 78.74 79.85 60.25 77.11 76.33
Cash Conversion Cycle (CCC)		 240.96 239.72 271.14 287.44 285.45 293.63 246.78 254.60 217.33 279.09 241.30
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 227 210 215 263 257 260 249 286 655 574 522
Invested Capital Turnover		 1.74 1.88 2.04 1.89 1.77 1.57 1.82 1.72 1.58 1.30 1.50
Increase / (Decrease) in Invested Capital		 -1.74 -17 5.92 48 -5.98 2.82 -11 37 369 -81 -52
Enterprise Value (EV)		 677 591 916 921 810 734 526 360 552 738 673
Market Capitalization		 741 645 997 993 880 831 614 411 495 667 600
Book Value per Share		 $15.37 $14.78 $16.27 $17.73 $17.19 $18.46 $17.06 $16.84 $16.29 $13.17 $11.36
Tangible Book Value per Share		 $12.25 $11.36 $12.76 $11.16 $10.62 $10.98 $10.78 $10.90 $7.79 $5.48 $4.60
Total Capital		 290 263 297 335 328 357 337 337 693 660 607
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 94 157 157
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 93 157 157
Net Debt		 -64 -54 -81 -72 -70 -97 -88 -51 57 71 72
Capital Expenditures (CapEx)		 22 16 15 14 19 15 18 23 62 35 35
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 67 57 91 87 105 70 76 122 219 179 161
Debt-free Net Working Capital (DFNWC)		 130 111 172 159 176 166 164 172 256 265 246
Net Working Capital (NWC)		 130 111 172 159 176 166 164 172 255 265 246
Net Nonoperating Expense (NNE)		 0.26 0.82 1.95 4.35 15 -6.90 33 10 54 67 35
Net Nonoperating Obligations (NNO)		 -64 -54 -81 -72 -70 -97 -88 -51 57 71 72
Total Depreciation and Amortization (D&A)		 23 22 22 20 28 34 33 32 97 88 83
Debt-free, Cash-free Net Working Capital to Revenue		 16.80% 13.91% 21.03% 19.10% 22.89% 17.13% 16.33% 26.41% 29.35% 22.38% 19.61%
Debt-free Net Working Capital to Revenue		 32.85% 27.07% 39.74% 35.04% 38.19% 40.95% 35.24% 37.41% 34.41% 33.10% 29.96%
Net Working Capital to Revenue		 32.85% 27.07% 39.74% 35.04% 38.19% 40.95% 35.24% 37.41% 34.24% 33.10% 29.96%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.15) $0.17 $0.34 $0.73 ($1.51) $0.13 ($1.95) ($0.98) ($4.12) ($3.30) ($2.33)
Adjusted Weighted Average Basic Shares Outstanding		 18.37M 18.14M 18.12M 18.49M 18.90M 19.27M 19.69M 20.05M 36.73M 38.13M 39.60M
Adjusted Diluted Earnings per Share		 ($0.15) $0.17 $0.34 $0.72 ($1.51) $0.13 ($1.95) ($0.98) ($4.12) ($3.30) ($2.33)
Adjusted Weighted Average Diluted Shares Outstanding		 18.37M 18.46M 18.50M 18.91M 18.90M 19.39M 19.69M 20.05M 36.73M 38.13M 39.60M
Adjusted Basic & Diluted Earnings per Share		 ($0.15) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 18.80M 17.95M 18.41M 19.06M 19.18M 19.51M 19.85M 36.46M 37.41M 39.02M 40.14M
Normalized Net Operating Profit after Tax (NOPAT)		 6.48 25 29 18 -13 -4.39 -5.82 -9.29 -97 -59 -57
Normalized NOPAT Margin		 1.63% 6.05% 6.59% 4.01% -2.86% -1.08% -1.25% -2.02% -13.07% -7.41% -6.93%
Pre Tax Income Margin		 2.15% 4.64% 8.39% 5.05% -5.88% -0.09% -2.91% -3.84% -19.94% -15.49% -11.04%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 18.40 0.00 88.48 28.64 -220.71 0.85 -6.35 -12.75 -16.23 -3.18 -4.19
NOPAT to Interest Expense		 -5.21 0.00 19.66 21.93 -107.78 -1.77 -3.17 -7.21 -11.28 -2.00 -3.26
EBIT Less CapEx to Interest Expense		 -27.40 0.00 53.23 12.22 -376.43 -5.38 -16.03 -30.73 -23.42 -4.36 -6.17
NOPAT Less CapEx to Interest Expense		 -51.01 0.00 -15.60 5.52 -263.49 -8.00 -12.85 -25.19 -18.47 -3.18 -5.24
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -17.77% 0.00% 0.00%
Augmented Payout Ratio		 -412.07% 2,075.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -17.77% 0.00% 0.00%

Quarterly Metrics And Ratios for Orthofix Medical

This table displays calculated financial ratios and metrics derived from Orthofix Medical's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - 39,022,492.00 39,180,833.00 39,494,265.00 39,599,659.00 40,144,397.00 40,421,652.00
DEI Adjusted Shares Outstanding		 - - - - - 39,022,492.00 39,180,833.00 39,494,265.00 39,599,659.00 40,144,397.00 40,421,652.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - -1.36 -0.36 -0.58 -0.06 -0.52 -0.39
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 62.88% 7.65% 6.20% 6.85% 8.33% 2.67% 2.27% 4.59% 1.97% 1.58% 3.85%
EBITDA Growth		 361.37% 66.02% 27.94% 65.42% 141.10% -6.42% 187.48% -92.09% 10.68% 94.82% -29.45%
EBIT Growth		 -159.68% 48.15% 25.20% 20.08% 15.72% -55.59% 62.53% 17.95% 114.60% 68.15% 13.25%
NOPAT Growth		 -65.84% 50.87% 32.01% 22.70% 37.34% -66.59% 35.75% 9.80% 104.30% 70.46% 49.17%
Net Income Growth		 -213.99% 40.89% 15.18% 5.09% -31.44% -47.40% 57.90% 16.77% 92.38% 60.62% -12.19%
EPS Growth		 -62.86% 44.44% 17.76% 7.79% -33.33% -42.11% 59.09% 19.72% 93.42% 61.48% -8.33%
Operating Cash Flow Growth		 -385.09% 45.34% 262.87% 2,346.75% 454.50% 1.10% 29.55% 6.26% 16.72% 4.25% -153.48%
Free Cash Flow Firm Growth		 -752.59% 95.34% 100.20% 106.91% 119.08% 443.81% 9,520.57% 147.21% -28.07% -87.21% -106.93%
Invested Capital Growth		 129.01% -0.02% -2.79% -6.13% -12.35% -15.83% -13.92% -12.76% -9.07% -3.44% -0.06%
Revenue Q/Q Growth		 8.19% -5.26% 5.31% -1.01% 9.69% -10.21% 4.89% 1.24% 6.94% -10.55% 7.23%
EBITDA Q/Q Growth		 240.10% -274.02% 21.34% 81.97% 1,076.82% -176.81% 164.66% -139.59% 662.85% -103.60% 980.29%
EBIT Q/Q Growth		 34.54% -74.43% 10.44% 21.84% 30.97% -222.02% 78.43% -71.14% 112.28% -802.64% 41.25%
NOPAT Q/Q Growth		 25.09% -60.18% 15.10% 24.12% 39.27% -325.83% 67.26% -6.52% 102.90% -3,022.27% 43.65%
Net Income Q/Q Growth		 23.16% -62.44% 7.15% 18.11% -6.42% -82.17% 73.48% -61.88% 90.25% -840.95% 24.44%
EPS Q/Q Growth		 25.97% -66.67% 7.37% 19.32% -7.04% -77.63% 73.33% -58.33% 91.23% -940.00% 25.00%
Operating Cash Flow Q/Q Growth		 -1,503.35% -177.79% 148.31% 29.91% 103.32% -177.50% 163.29% 6.56% 123.33% -163.58% 64.66%
Free Cash Flow Firm Q/Q Growth		 1.31% 94.66% 103.94% 3,232.80% 172.45% -3.82% 10.16% -14.36% -20.73% -82.89% -159.70%
Invested Capital Q/Q Growth		 0.54% 0.57% -3.63% -3.67% -6.12% -3.43% -1.45% -2.37% -2.14% 2.55% 2.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 68.63% 67.46% 67.84% 68.69% 69.02% 62.80% 68.69% 72.23% 71.09% 70.94% 70.97%
EBITDA Margin		 3.24% -5.95% -4.45% -0.81% 7.21% -6.17% 3.80% -1.49% 7.83% -0.31% 2.58%
Operating Margin		 -9.20% -15.55% -12.54% -9.61% -5.32% -25.24% -7.88% -8.29% 0.22% -7.34% -3.86%
EBIT Margin		 -8.82% -16.23% -13.80% -10.90% -6.86% -24.59% -5.06% -8.55% 0.98% -7.71% -4.23%
Profit (Net Income) Margin		 -11.14% -19.10% -16.84% -13.93% -13.52% -27.42% -6.93% -11.09% -1.01% -10.63% -7.49%
Tax Burden Percent		 100.95% 102.42% 103.35% 102.82% 98.10% 101.84% 99.00% 102.39% 101.37% 100.36% 105.34%
Interest Burden Percent		 125.17% 114.89% 118.03% 124.32% 200.88% 109.46% 138.45% 126.63% -101.53% 137.34% 168.28%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -10.20% -12.53% -10.50% -8.34% -4.84% -23.42% -7.55% -8.29% 0.24% -7.78% -4.12%
ROIC Less NNEP Spread (ROIC-NNEP)		 -327.26% -49.50% -41.72% -31.50% -37.86% -43.82% -10.79% -20.55% -3.34% -18.75% -13.95%
Return on Net Nonoperating Assets (RNNOA)		 -2.06% -3.36% -3.61% -3.37% -4.39% -7.89% -1.91% -3.76% -0.50% -4.13% -3.23%
Return on Equity (ROE)		 -12.26% -15.89% -14.10% -11.71% -9.24% -31.31% -9.46% -12.05% -0.27% -11.91% -7.35%
Cash Return on Invested Capital (CROIC)		 -99.11% -11.53% -7.71% -3.80% 3.53% 5.18% 3.68% 2.22% -0.90% -2.53% -4.95%
Operating Return on Assets (OROA)		 -9.49% -13.51% -11.93% -9.62% -6.03% -22.89% -4.76% -8.23% 0.93% -7.45% -4.12%
Return on Assets (ROA)		 -12.00% -15.89% -14.55% -12.30% -11.88% -25.51% -6.52% -10.67% -0.95% -10.26% -7.30%
Return on Common Equity (ROCE)		 -12.26% -15.89% -14.10% -11.71% -9.24% -31.31% -9.46% -12.05% -0.27% -11.91% -7.35%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -22.18% -22.07% -22.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -21 -17 -13 -8.03 -34 -11 -12 0.35 -10 -5.69
NOPAT Margin		 -6.44% -10.89% -8.78% -6.73% -3.73% -17.67% -5.52% -5.80% 0.16% -5.14% -2.70%
Net Nonoperating Expense Percent (NNEP)		 317.07% 36.97% 31.23% 23.16% 33.02% 20.40% 3.24% 12.26% 3.58% 10.97% 9.83%
Return On Investment Capital (ROIC_SIMPLE)		 -1.85% - - - -1.22% -5.56% -1.82% -1.99% 0.06% -1.54% -0.87%
Cost of Revenue to Revenue		 32.04% 32.54% 32.16% 31.31% 30.98% 37.20% 31.31% 27.77% 28.91% 29.06% 29.03%
SG&A Expenses to Revenue		 211.11% 16.78% 17.12% 17.07% 200.93% 68.67% 67.20% 72.02% 62.19% 68.58% 65.44%
R&D to Revenue		 9.51% 10.33% 9.09% 8.80% 8.72% 10.21% 7.84% 7.18% 6.99% 7.79% 7.56%
Operating Expenses to Revenue		 77.83% 83.02% 80.38% 78.30% 74.34% 88.04% 76.57% 80.52% 70.87% 78.28% 74.83%
Earnings before Interest and Taxes (EBIT)		 -18 -31 -27 -21 -15 -48 -10 -18 2.16 -15 -8.91
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 6.45 -11 -8.83 -1.59 16 -12 7.72 -3.06 17 -0.62 5.45
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.83 0.95 0.91 1.13 1.33 1.39 0.95 1.31 1.33 1.06 0.86
Price to Tangible Book Value (P/TBV)		 1.73 2.07 2.05 2.63 3.19 3.49 2.37 3.36 3.29 2.69 2.20
Price to Revenue (P/Rev)		 0.66 0.72 0.65 0.76 0.83 0.79 0.54 0.71 0.73 0.56 0.44
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.84 0.96 0.92 1.12 1.29 1.32 0.96 1.25 1.29 1.05 0.89
Enterprise Value to Revenue (EV/Rev)		 0.74 0.83 0.76 0.87 0.92 0.91 0.65 0.82 0.82 0.68 0.58
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 53.94 80.93 67.71 26.39 25.63
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 28.64 28.19 18.33 22.79 20.17 16.44 29.92
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 34.04 23.33 24.14 52.73 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.16 0.21 0.22 0.23 0.31 0.34 0.34 0.36 0.35 0.51 0.52
Long-Term Debt to Equity		 0.16 0.20 0.21 0.21 0.31 0.34 0.34 0.36 0.35 0.51 0.52
Financial Leverage		 0.01 0.07 0.09 0.11 0.12 0.18 0.18 0.18 0.15 0.22 0.23
Leverage Ratio		 1.48 1.48 1.50 1.55 1.65 1.68 1.71 1.76 1.83 1.91 1.93
Compound Leverage Factor		 1.85 1.70 1.77 1.93 3.32 1.84 2.37 2.22 -1.86 2.63 3.24
Debt to Total Capital		 13.61% 17.17% 17.77% 18.38% 23.79% 25.50% 25.52% 26.22% 25.91% 33.71% 34.05%
Short-Term Debt to Total Capital		 0.18% 0.45% 0.71% 0.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 13.43% 16.71% 17.07% 17.41% 23.79% 25.50% 25.52% 26.22% 25.91% 33.71% 34.05%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 86.39% 82.83% 82.23% 81.62% 76.21% 74.50% 74.48% 73.78% 74.09% 66.29% 65.95%
Debt to EBITDA		 -2.17 -5.46 -6.48 -7.80 -25.77 -23.02 16.13 19.01 15.85 10.41 11.67
Net Debt to EBITDA		 -1.30 -4.10 -4.90 -5.65 -11.70 -14.15 9.07 11.03 7.28 4.73 6.17
Long-Term Debt to EBITDA		 -2.14 -5.32 -6.22 -7.39 -25.77 -23.02 16.13 19.01 15.85 10.41 11.67
Debt to NOPAT		 -0.97 -1.55 -1.74 -1.85 -2.65 -2.15 -2.36 -2.40 -2.76 -6.73 -8.09
Net Debt to NOPAT		 -0.58 -1.17 -1.31 -1.34 -1.20 -1.32 -1.33 -1.40 -1.27 -3.05 -4.28
Long-Term Debt to NOPAT		 -0.96 -1.51 -1.67 -1.75 -2.65 -2.15 -2.36 -2.40 -2.76 -6.73 -8.09
Altman Z-Score		 1.76 1.74 1.62 1.78 1.79 1.63 1.40 1.52 1.62 1.28 1.17
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.54 2.65 2.48 2.39 2.57 2.71 2.67 2.47 2.45 2.87 2.84
Quick Ratio		 0.98 1.01 0.97 0.96 1.29 1.32 1.32 1.21 1.28 1.60 1.53
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -382 -20 0.80 27 73 70 77 66 52 8.97 -5.35
Operating Cash Flow to CapEx		 -40.93% -176.37% 96.15% 219.30% 245.47% -273.03% 163.72% 125.22% 254.64% -165.18% -49.21%
Free Cash Flow to Firm to Interest Expense		 -84.89 -4.47 0.16 5.14 4.89 15.56 19.55 14.13 12.05 1.58 -0.88
Operating Cash Flow to Interest Expense		 -1.49 -4.08 1.82 2.24 1.59 -4.08 2.95 2.65 6.37 -3.11 -1.02
Operating Cash Flow Less CapEx to Interest Expense		 -5.12 -6.39 -0.07 1.22 0.94 -5.58 1.15 0.53 3.87 -4.99 -3.10
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.08 0.83 0.86 0.88 0.88 0.93 0.94 0.96 0.94 0.97 0.97
Accounts Receivable Turnover		 7.07 6.35 6.48 6.55 6.08 6.25 6.35 6.40 6.08 6.12 6.28
Inventory Turnover		 1.62 1.16 1.17 1.17 1.23 1.34 1.38 1.37 1.42 1.37 1.34
Fixed Asset Turnover		 6.86 5.14 5.23 5.23 5.35 5.57 5.71 5.91 6.11 6.45 6.41
Accounts Payable Turnover		 6.06 4.99 4.98 5.00 4.73 5.17 5.53 5.32 4.78 4.84 4.40
Days Sales Outstanding (DSO)		 51.66 57.47 56.31 55.70 59.99 58.41 57.50 57.03 60.02 59.62 58.13
Days Inventory Outstanding (DIO)		 225.92 313.34 311.66 311.40 296.21 271.79 264.80 267.10 257.61 266.31 272.88
Days Payable Outstanding (DPO)		 60.25 73.20 73.29 73.07 77.11 70.66 65.99 68.57 76.33 75.49 82.93
Cash Conversion Cycle (CCC)		 217.33 297.61 294.68 294.04 279.09 259.53 256.31 255.56 241.30 250.44 248.09
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 655 659 635 612 574 555 547 534 522 536 546
Invested Capital Turnover		 1.58 1.15 1.20 1.24 1.30 1.33 1.37 1.43 1.50 1.51 1.52
Increase / (Decrease) in Invested Capital		 369 -0.14 -18 -40 -81 -104 -88 -78 -52 -19 -0.34
Enterprise Value (EV)		 552 632 587 682 738 733 525 669 673 561 487
Market Capitalization		 495 543 498 596 667 636 437 578 600 460 369
Book Value per Share		 $16.29 $15.25 $14.55 $13.78 $13.17 $11.74 $11.70 $11.20 $11.36 $10.84 $10.62
Tangible Book Value per Share		 $7.79 $7.02 $6.47 $5.93 $5.48 $4.67 $4.71 $4.35 $4.60 $4.26 $4.16
Total Capital		 693 689 664 644 660 615 615 600 607 657 651
Total Debt		 94 118 118 118 157 157 157 157 157 221 222
Total Long-Term Debt		 93 115 113 112 157 157 157 157 157 221 222
Net Debt		 57 89 89 86 71 96 88 91 72 100 117
Capital Expenditures (CapEx)		 16 11 9.34 5.32 9.67 6.74 7.11 9.90 11 11 13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 219 222 206 198 179 186 179 168 161 180 185
Debt-free Net Working Capital (DFNWC)		 256 251 235 231 265 246 247 234 246 300 289
Net Working Capital (NWC)		 255 248 230 224 265 246 247 234 246 300 289
Net Nonoperating Expense (NNE)		 9.35 15 16 14 21 19 2.88 11 2.57 11 10
Net Nonoperating Obligations (NNO)		 57 89 89 86 71 96 88 91 72 100 117
Total Depreciation and Amortization (D&A)		 24 19 19 20 30 36 18 15 15 15 14
Debt-free, Cash-free Net Working Capital to Revenue		 29.35% 29.26% 26.73% 25.29% 22.38% 23.09% 22.10% 20.58% 19.61% 21.76% 22.17%
Debt-free Net Working Capital to Revenue		 34.41% 33.15% 30.48% 29.45% 33.10% 30.60% 30.59% 28.64% 29.96% 36.41% 34.70%
Net Working Capital to Revenue		 34.24% 32.73% 29.87% 28.65% 33.10% 30.60% 30.59% 28.64% 29.96% 36.41% 34.70%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.57) ($0.95) ($0.88) ($0.71) ($0.76) ($1.35) ($0.36) ($0.57) ($0.05) ($0.52) ($0.39)
Adjusted Weighted Average Basic Shares Outstanding		 36.73M 37.74M 38.02M 38.49M 38.13M 39.19M 39.50M 39.77M 39.60M 40.45M 40.91M
Adjusted Diluted Earnings per Share		 ($0.57) ($0.95) ($0.88) ($0.71) ($0.76) ($1.35) ($0.36) ($0.57) ($0.05) ($0.52) ($0.39)
Adjusted Weighted Average Diluted Shares Outstanding		 36.73M 37.74M 38.02M 38.49M 38.13M 39.19M 39.50M 39.77M 39.60M 40.45M 40.91M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 37.41M 37.53M 38.17M 38.21M 39.02M 39.18M 39.49M 39.60M 40.14M 40.42M 40.73M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -21 -17 -13 -8.03 -34 -11 -12 0.35 -10 -5.69
Normalized NOPAT Margin		 -6.44% -10.89% -8.78% -6.73% -3.73% -17.67% -5.52% -5.80% 0.16% -5.14% -2.70%
Pre Tax Income Margin		 -11.03% -18.65% -16.29% -13.55% -13.78% -26.92% -7.00% -10.83% -1.00% -10.59% -7.11%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -3.90 -6.72 -5.55 -4.11 -0.99 -10.57 -2.60 -3.76 0.50 -2.68 -1.46
NOPAT to Interest Expense		 -2.85 -4.51 -3.53 -2.54 -0.54 -7.59 -2.84 -2.55 0.08 -1.78 -0.94
EBIT Less CapEx to Interest Expense		 -7.53 -9.03 -7.44 -5.13 -1.64 -12.06 -4.40 -5.87 -2.00 -4.56 -3.54
NOPAT Less CapEx to Interest Expense		 -6.48 -6.82 -5.42 -3.56 -1.19 -9.09 -4.64 -4.66 -2.42 -3.67 -3.01
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -17.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -17.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Orthofix Medical’s recent statements show a company making progress on revenue growth and gross margins, but it remains unprofitable and is using cash. Revenue reached $210.9 million in Q2 2026, up 3.8% from $203.1 million in the restated Q2 2025 and substantially above the roughly $114.0 million reported in Q3 2022. However, the latest quarter still produced a $15.8 million net loss, or $0.39 per diluted share.

  • Revenue has generally trended higher. Quarterly revenue increased from $175.2 million in Q1 2023 to $210.9 million in Q2 2026. Q2 2026 revenue also improved sequentially by approximately 7.2% from Q1 2026.
  • Gross margins have improved. Q2 2026 gross profit was $149.7 million, representing a margin of approximately 71.0%, compared with about 68.7% in Q2 2025 and 60.1% in Q1 2024.
  • Operating losses have narrowed over time. The Q2 operating loss improved to $8.1 million from $16.0 million in Q2 2025, $24.9 million in Q2 2024 and $36.6 million in Q2 2023.
  • Cash resources are stronger than they were in 2024 and early 2025. Cash and equivalents stood at $103.8 million at June 30, 2026, compared with $65.6 million at June 30, 2025 and $26.4 million at June 30, 2024.
  • Liquidity remains adequate on a current-ratio basis. Current assets of $446.1 million exceeded current liabilities of $157.0 million by a wide margin, producing a current ratio of approximately 2.8.
  • Management continues to invest in productive capacity. Capital expenditures were $12.6 million in Q2 2026, and net property, plant and equipment increased to $130.8 million from $125.3 million at the end of Q1. These investments could support growth, although they also contribute to cash usage.
  • Working-capital trends require monitoring. Inventory increased to $184.5 million in Q2 2026 from $177.8 million in Q1, while accounts receivable declined modestly to $135.8 million. The increase in inventory could support sales, but it also ties up capital if turnover slows.
  • Orthofix remains consistently unprofitable. The company has reported net losses in each of the supplied comparable quarters. Although the Q2 2026 loss improved from Q1 2026’s $20.9 million, it was larger than the $14.1 million loss in Q2 2025.
  • Operating cash flow has deteriorated recently. Q2 2026 operating cash flow was negative $6.2 million, compared with positive operating cash flow of $11.6 million in Q2 2025. After $12.6 million of capital expenditures, the business generated negative free cash flow of roughly $18.9 million for the quarter.
  • Debt and accumulated losses remain important risks. Long-term debt increased to $221.6 million at June 30, 2026, up from $157.0 million in Q3 2025, following a $64.0 million debt issuance in Q1 2026. Retained earnings were negative $405.0 million, while interest expense reached $6.1 million in Q2 2026.

Overall, the financial trend is mixed. Orthofix is producing higher revenue, stronger gross margins and smaller operating losses than it did several years ago. Nevertheless, the company has not yet converted those improvements into net profitability or consistently positive free cash flow. Investors should focus on whether revenue growth can accelerate enough to absorb selling, general and administrative costs, while also watching debt levels, interest expense and quarterly cash burn. Several historical income statement and cash flow figures are identified as restated in the supplied data, so comparisons should be interpreted with that reporting caveat.

10/02/26 08:52 PM ETAI Generated. May Contain Errors.

Orthofix Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Orthofix Medical's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Orthofix Medical's net income appears to be on a downward trend, with a most recent value of -$92.19 million in 2025, falling from -$2.81 million in 2015. The previous period was -$126.00 million in 2024. View Orthofix Medical's forecast to see where analysts expect Orthofix Medical to go next.

Orthofix Medical's total operating income in 2025 was -$81.43 million, based on the following breakdown:
  • Total Gross Profit: $566.02 million
  • Total Operating Expenses: $647.45 million

Over the last 10 years, Orthofix Medical's total revenue changed from $396.49 million in 2015 to $822.31 million in 2025, a change of 107.4%.

In the past 13 quarters, Orthofix Medical's cash and equivalents has ranged from $26.37 million in Q2 2024 to $120.28 million in Q1 2026, and is currently $103.81 million as of their latest financial filing in Q2 2026.

Orthofix Medical had total debt of $157.39 million at the end of 2025, a 0.2% increase from 2024, and none in 2015.

Over the last 10 years, Orthofix Medical's book value per share changed from 15.37 in 2015 to 11.36 in 2025, a change of -26.1%.


Related Companies

Financial statements for NASDAQ:OFIX last updated on 8/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
WATCH THIS BEFORE DECEMBER 8th!!
James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...
Paradigm Press | Sponsoredtc pixel
A new kind of civil war is coming after election day?
Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...
Stansberry Research | Sponsoredtc pixel
How Elon’s Empire Ends (and how to profit)
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel